Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02335814 · ClinicalTrials.gov registry record · Phase 1
First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 1 study, sponsored by RAPT Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 51
- Enrollment target
NCT02335814 is a Phase 1 study that was terminated before completion, run by RAPT Therapeutics. The registered enrollment target is 51 participants.
The verdict
NCT02335814, a Phase 1 study, was terminated before completion, sponsored by RAPT Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 51 participants
- Enrollment target
Study Summary
This first-in-human (FIH) clinical trial is a Phase 1/1b, open-label, sequential-group, dose-escalation and cohort expansion study evaluating the safety, PK, PD, and antitumor activity of FLX925 in subjects with relapsed or refractory AML.
Interventions
- DRUG FLX925
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2015-04-08 |
| Est. Completion | 2017-05-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02335814
The ClinicalTrials.gov registry entry for NCT02335814 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is RAPT Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FLX925 is the first listed.
NCT02335814 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02335814 about?
NCT02335814 is a clinical study titled "First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia". This first-in-human (FIH) clinical trial is a Phase 1/1b, open-label, sequential-group, dose-escalation and cohort expansion study evaluating the safety, PK, PD, and antitumor activity of FLX925 in subjects with relapsed or refractory AML.
What is the current status of trial NCT02335814?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2015-04-08. Estimated completion is 2017-05-03.
What interventions are being tested in trial NCT02335814?
The interventions under investigation include: FLX925 (DRUG).
Who is sponsoring clinical trial NCT02335814?
This trial is sponsored by RAPT Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.